[Pneumococcal infections and vaccination in patients with systemic autoimmune and/or inflammatory diseases].
Patients with systemic autoimmune and/or inflammatory diseases have an increased risk of infections, particularly pneumoccocal invasive infections. Vaccination can prevent these infections. Available data about immunogenicity and safety of pneumococcal polysaccharide vaccine in these patients indicate that, it remains well tolerated and most of the time immunogenic, even if the antibody response is lower compared to healthy controls. These data encourage to vaccinate these patients with pneumococcal vaccine. However, the lack of data confirming the clinical efficacy of this vaccination, the theoretical risk of disease relapse following vaccine administration and the lack of specific recommendations guiding the decision to vaccinate these patients contribute to the low vaccine coverage. More immunogenic vaccine strategy should be evaluated in patients with systemic autoimmune and/or inflammatory diseases to provide better vaccine coverage.
Duchet-Niedziolka
Paula
P
Centre d'Investigation Clinique de Vaccinologie Cochin Pasteur, Pôle de Médecine, Groupe Hospitalier Cochin Saint-Vincent-de-Paul, Assistance Publique-Hôpitaux de Paris, Paris Cedex 14, France.
Hanslik
Thomas
T
Aouba
Achille
A
Le Guern
Véronique
V
Guillevin
Loïc
L
Launay
Odile
O
D001327:Autoimmune Diseases / Q000150:complications / Q000276:immunology*; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000276:immunology*; D010919:Placebos; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000627:therapeutic use*; D012008:Recurrence; D015203:Reproducibility of Results; D012307:Risk Factors; D014611:Vaccination / Q000379:methods
D010919:Placebos; D022242:Pneumococcal Vaccines